Drugs that contain Binimetinib
1. Mektovi patents expiration
MEKTOVI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8178693 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(1 year, 1 month ago) | |
| US7777050 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2024
(a month ago) | |
| US9562016 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8193229 | ARRAY BIOPHARMA INC | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(1 year, 1 month ago) | |
| US8513293 | ARRAY BIOPHARMA INC | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
Mar, 2023
(1 year, 1 month ago) | |
| US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
| US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(7 years from now) | |
| US9598376 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
| US9980944 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma; Mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of pati...
Dosage: TABLET;ORAL
How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage
MEKTOVI family patents
